CONNECT WITH US
HealthTech

HealthTech

Setara gets $90M to continue rare disease pipeline spun out of Jazz's Actio deal

Endpoints News logo

Published on

Add as a preferred source on Google
Setara gets $90M to continue rare disease pipeline spun out of Jazz's Actio deal

Se­tara gets $90M to con­tin­ue rare dis­ease pipeline spun out of Jaz­z's Ac­tio deal

Af­ter ship­ping its pre­ci­sion epilep­sy drug to Jazz Phar­ma­ceu­ti­cals, Ac­tio Bio­sciences has spun out the re­main­der of its ge­net­ics-dri­ven pipeline in­to a new com­pa­ny called …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Ex­clu­sive: Dren Bio nabs $350M for po­ten­tial 2027 launch of blood can­cer drug October 29, 2026

Flag­ship Pi­o­neer­ing merges three of its com­pa­nies for AI drug dis­cov­ery October 29, 2026

For­ma­tion Bio un­veils $600M fund to li­cense and test more drugs October 28, 2026

Af­ter Be Bio shut­down, its CEO heads to Or­bis; Enan­ta's long­time chief Jay Lu­ly to re­tire

Sanofi has no plans for a 'ma­jor' over­haul as Dupix­en­t's patent cliff looms

One-per­son biotechs and an 'age of mir­a­cles': An­throp­ic re­veals next leg of its bio­phar­ma vi­sion



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.